INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
December 16, 2024 – INCATE (the INCubator for Antibacterial Therapies in Europe), is delighted to announce the extension of its strategic partnership with the Kineticos AMR Accelerator Fund I (KAMRA I). Building on the successful [...]
December 16, 2024 – INCATE (INCubator for Antibacterial Therapies in Europe) is pleased to announce [...]
Just before turning the page to 2025, it's a moment to reflect on the progress [...]
We are thrilled to announce a significant milestone for Invitris—a $650,000 deal plus royalties with [...]
2024 has been a transformative year for Xiretsa, filled with exciting milestones and promising opportunities. [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
